共 7 条
- [3] Effect of guselkumab on serum biomarkers in Japanese palmoplantar pustulosis patients in a randomized phase 3 study JEADV CLINICAL PRACTICE, 2023, 2 (01): : 59 - 72
- [4] Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (02): : 182 - 189
- [5] Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study JOURNAL OF DERMATOLOGY, 2025, 52 (04): : 593 - 602